Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00261287
Recruitment Status : Completed
First Posted : December 5, 2005
Last Update Posted : November 30, 2016
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of ciclesonide nasal spray for long term use in relieving symptoms in perennial allergic rhinitis.

Condition or disease Intervention/treatment Phase
Hay Fever Perennial Allergic Rhinitis Drug: Ciclesonide Phase 3

Study Type : Interventional  (Clinical Trial)
Enrollment : 102 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Tolerability of Ciclesonide (200 mcg Once Daily), Applied as a Nasal Spray for Twelve Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age
Study Start Date : November 2005
Actual Primary Completion Date : June 2006
Actual Study Completion Date : June 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Ciclesonide

Primary Outcome Measures :
  1. Safety and tolerability of ciclesonide nasal spray

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   2 Years to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • General good health, other than perennial allergic rhinitis
  • History and diagnosis of perennial allergic rhinitis by skin prick test
  • History of perennial allergic rhinitis for a minimum of 90 days immediately before the screening visit

Main Exclusion Criteria:

  • Participation in any investigational drug trial within the 30 days before the screening visit
  • Use of any disallowed concomitant medications within the prescribed withdrawal periods before the screening visit
  • A known hypersensitivity to any corticosteroid

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00261287

United States, California
Altana Pharma/Nycomed
Long Beach, California, United States, 90806
United States, Illinois
Altana Pharma/Nycomed
Normal, Illinois, United States, 61761
United States, Texas
Altana Pharma/Nycomed
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Study Director: AstraZeneca AstraZeneca AstraZeneca

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT00261287     History of Changes
Other Study ID Numbers: BY9010/M1-416
First Posted: December 5, 2005    Key Record Dates
Last Update Posted: November 30, 2016
Last Verified: October 2016

Keywords provided by AstraZeneca:
Hay Fever
Allergic Rhinitis
Perennial Allergic Rhinitis

Additional relevant MeSH terms:
Rhinitis, Allergic
Rhinitis, Allergic, Perennial
Rhinitis, Allergic, Seasonal
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Allergic Agents